Sign in

You're signed outSign in or to get full access.

Marjorie Bowen

About Marjorie Bowen

Marjorie L. Bowen, age 59, has served on CBL’s Board since November 1, 2021; she is an Independent Director, Chair of the Audit Committee, and a member of the Nominating/Corporate Governance Committee. Bowen is a former Managing Director of Houlihan Lokey’s fairness opinion practice (joined 1989; Managing Director 2000–2007), with extensive REIT and restructuring experience, and has chaired Audit, Special, and transaction committees; she holds an MBA from the University of Chicago Booth School of Business and a BA, cum laude, from Colgate University .

Past Roles

OrganizationRoleTenureCommittees/Impact
Houlihan LokeyManaging Director, Fairness Opinion Practice2000–2007; joined firm 1989Led fairness opinion practice; significant public REIT experience; chaired special and transaction committees across boards
Various companies (board service)Director; committee leadership on Audit, Restructuring, Finance, Strategic ReviewVarious (see External Roles)Chaired Audit and Special Committees; “financial expert” credentials (NYSE/NASDAQ)

External Roles

CompanyRoleTenureNotes
Diebold Nixdorf, IncorporatedDirector2023–2025Prior board service
Bed Bath & Beyond Inc.Director2022–2023Prior board service
Sequential Brands Group, Inc.Director2021–2022Prior board service
Centric Brands, Inc.Director2020Prior board service
Genesco, Inc.Director2018–2019Prior board service
Navient CorporationDirector2019–2020Prior board service
ShoreTel Inc.Director2016–2017Prior board service

Board Governance

  • Independence: Board determined Bowen is independent under SEC and NYSE standards; all Audit Committee members (including Bowen) are independent and designated “audit committee financial experts” .
  • Committee roles: Audit Chair; Nominating/Corporate Governance member; Audit Committee met five times in 2024; Nominating/Corporate Governance met five times in 2024 .
  • Attendance: Board met six times in 2024; each director attended >75% of aggregate Board and committee meetings on which they served .
  • Independent director executive sessions: Six executive sessions in 2024, chaired by the Non‑Executive Chairman (Contis) .
Committee2024 MembersChair2024 MeetingsIndependence/Financial Expert Status
AuditMarjorie L. Bowen; David J. Contis; Robert G. Gifford; Michael A. TorresBowen5All independent; all qualify as “audit committee financial expert”
Nominating/Corporate GovernanceDavid M. Fields; Marjorie L. Bowen; Jeffrey A. KivitzFields5All independent; oversees ESG and director nominations
CompensationRobert G. Gifford; David M. Fields; Jeffrey A. Kivitz; Michael A. TorresGifford3All independent; no interlocks; uses Ferguson Partners as consultant

Fixed Compensation

Component (2024)Bowen Amount ($)Basis/Policy
Annual Cash Retainer75,000Standard non‑employee director retainer
Committee Chair Fee (Audit)25,000Audit Chair fee (chair receives in lieu of member fee)
Committee Member Fee (Nominating/CG)15,000Committee member fee
Total Cash Fees (sum)115,000Reported fees earned in 2024

Non‑employee director cash fee schedule effective Jan 1, 2023: $75,000 retainer; $15,000 per committee membership; $25,000 Audit Chair; $20,000 Compensation/Nominating Chair; $50,000 incremental fee for Non‑Executive Chairman (equity component eliminated in Feb 2024) .

Performance Compensation

Equity AwardGrant DateShares GrantedGrant Date Fair Value per Share ($)Grant Date Fair Value ($)Vesting
Annual Restricted Stock (RS)Dec 15, 20244,01731.12125,009Vests Jan 1, 2026 (following 2025 Annual Service Period)
  • Non‑employee director annual equity award policy: $125,000 in restricted common stock granted December 15 each year for prospective service in the upcoming calendar year; shares vest on January 1 following conclusion of that year’s service; directors have voting and dividend rights during restriction; forfeiture applies if service ceases (death/disability and change‑in‑control exceptions) .
  • Outstanding director RS balances: As of Dec 31, 2024 Bowen held 9,232 restricted shares; as of April 8, 2025 her restricted balance reflected 4,017 shares (prior grants vesting per schedule) .

Other Directorships & Interlocks

AreaDetail
Compensation committee interlocksNone; all Compensation Committee members are independent; no insider participation or external interlocks reported .
Potential interlocks/conflictsBoard noted Independent Directors (including Bowen) were initially recommended during Chapter 11 by an Ad Hoc Bondholder Group via Korn Ferry search; Board concluded these factors did not impair independence .

Expertise & Qualifications

  • Audit “financial expert” per SEC definition; NYSE independence; Audit Chair overseeing internal controls, auditor engagement, cybersecurity risk, and hedging oversight .
  • Deep restructuring/transaction experience; chaired Audit, Special, and strategic committees; finance, capital markets, and M&A skill set; MBA (Chicago Booth), BA cum laude (Colgate) .
  • Board skills matrix: financial literacy, risk oversight, corporate governance, corporate restructuring among core competencies .

Equity Ownership

HolderTotal Beneficial Ownership (shares)% of Shares OutstandingUnrestricted SharesRestricted SharesDate/Source
Marjorie L. Bowen30,094<1%26,0774,017April 8, 2025; Security Ownership Table and footnotes
Bowen – Restricted balance (FY-end)9,232N/AN/A9,232As of Dec 31, 2024; Director compensation note
  • Ownership guidelines: CBL maintains minimum stock ownership requirements for non‑employee directors; compliance valuation uses greater of cost, tax basis, or prior-year average closing price; PSUs/RSUs counted only after performance satisfied and exchange implemented; exceptions require committee chair approval .
  • Pledging/hedging: No pledging or hedging disclosures identified for Bowen in proxy materials .

Governance Assessment

  • Strengths

    • Independent director with audit “financial expert” designation; serves as Audit Chair overseeing auditor independence, internal controls, cybersecurity, and hedging — a strong signal of governance rigor .
    • Robust engagement: Board met six times; committees active (Audit 5; Nominating/CG 5); each director >75% attendance; independent director executive sessions held six times, supporting independent oversight .
    • Pay alignment for directors: Balanced cash/equity mix; time‑based RS aligns long‑term interests; committee chair premium appropriately recognizes workload; compensation benchmarked with independent consultant (Ferguson Partners) .
    • Ownership alignment: Meaningful personal holdings and ongoing annual RS grants; clear ownership guideline framework .
  • Watch items / potential conflicts

    • Chapter 11 selection pathway: Bowen (and certain others) were initially recommended by an Ad Hoc Bondholder Group; while Board affirmed independence, investors may monitor for perceived creditor influence in governance decisions. Board explicitly determined this does not impair independence .
    • Concentrated external holders: Significant 5%+ holders (e.g., Canyon, Oaktree, Vanguard, BlackRock, Amster) shape governance context; no specific conflicts identified for Bowen, but Audit Chair role implies heightened vigilance on related‑party matters (e.g., HGPI outlet JV transactions linked to Amster) .
  • Red flags

    • None disclosed for Bowen regarding related‑party transactions, low attendance, hedging/pledging, or compensation anomalies in the proxy .